10 February 2023
Visiongain has published a new report: Gynaecology Drugs Market Report 2023-2033: Forecasts by Disease (Gynaecology Cancers, Contraception, Female Infertility, Menopausal Disorders, Polycystic Ovary Syndrome (PCOS), Gynaecology Infections, Endometriosis, Other), by Therapeutics (Non-hormonal Therapies, Hormonal Therapies), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by Type (Generic, Branded) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis.
The Gynaecology Drugs market was valued at US$43,561 million in 2023 and is projected to grow at a CAGR of 5.1% during the forecast period 2023-2033.
Gaps in Knowledge Hampering the Growth
Uncertainties in Gynaecology cancer treatment encompasses several factors such as efficacy data; limited information about off-label use of drugs; and possible adverse events due to the use of drugs. Additionally, restraints include lack of sufficient data to develop understanding around hazards of infectious diseases in pregnancy and impact of SARS-CoV-2 infection. Furthermore, use of hormonal therapies come with number of side-effects such as depression, stress, bleeding, etc that exert a pressure on women. Eventually, physicians are reluctant to prescribe new treatments or medications hampering consequently affecting the uptake of therapies. Additionally, there is still an unmet need with respect to understanding the impact of medications and their possible side effects that urges for an increase in awareness.
How will this Report Benefit you?
Visiongain’s 340-page report provides 166 tables and 293 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the Gynaecology Drugs market, along with detailed segment analysis in the market. This new study will help you evaluate the overall global and regional market for Gynaecology Drugs. Get financial analysis of the overall market and different segments including type, process, upstream, downstream, and company size and capture higher market share. We believe that there are strong opportunities in this fast-growing Gynaecology Drugs market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.
What are the Current Market Drivers?
High prevalence of gynecological diseases
High prevalence of diseases related to Gynaecology is expected to increase the demand for advanced treatment of diseases and thus drive market growth. According to the study conducted by the Institute for Health Metrics and Evaluation (IHME), gynecological diseases led to 8,640 deaths worldwide in 2019. Furthermore, around 39.6% of all females (1.53 billion) were living with these diseases. Globally, cervical cancer contributed 487,300 new cases, uterine corpus cancer accounted for 233,300 new cases; ovarian cancer with 230,000 new cases while vagina, vulva, placenta, and ill-defined sites cancer contributed for 74,900 cases.
Where are the Market Opportunities?
Increased Demand for Gynaecology Drugs in Emerging Markets
Rise in purchasing power in developing countries has enhanced healthcare treatments leading to increased accessibility and affordability. For instance, in 2020, Mankind Pharma launched the first generic drug for dydrogesterone which is considered superior to progesterone and is indicated for more than ten gynaecological indications including sustenance of pregnancy during infertility treatments. After mankind Pharma several other pharma companies such as Emcure, Alkem, Torrent and Eris have entered this drug market. The branded version for this drug is named Duphaston from Abbott and is highly expensive. Thus, availability of new products is increasing the adoption among people from these regions enhancing growth of gynaecological drugs.
The major players operating in the Gynaecology Drugs market are Merck, Pfizer, GSK, AbbVie, Roche, Bayer Pharmaceuticals, Eli Lilly and Company, Janssen Pharma (Part of Johnson & Johnson), AstraZeneca, and Amgen. These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launch.
• On Sep 2022, Lynparza, developed by AstraZeneca and MSD, obtained approval for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer maintenance treatment in China.
• On August 2022, Bayer, received extension of 8 years for the supplemental New Drug Application (sNDA) for contraception – Mirena.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global Bioreactors market was estimated to be valued at US$ 9,9770.0 million in 2023 and is expected to register a CAGR of 12.2% from 2023 to 2033.
29 September 2023
The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.
27 September 2023
The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.
25 September 2023
The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.